Voyager Therapeutics, Inc. (NASDAQ:VYGR)
| Market Cap | 112.76M-56.0% |
| Revenue (ttm) | 34.46M-19.1% |
| Net Income | -107.73M+0.2% |
| EPS | -1.81+2.2% |
| Shares Out | 61.62M |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 943,583 |
| Open | 1.79 |
| Previous Close | 1.78 |
| Day's Range | 1.79 - 1.87 |
| 52-Week Range | 1.68 - 5.48 |
| Beta | 1.20 |
| Analysts | Buy |
| Price Target | 14.40(+686.89%) |
| Earnings Date | Nov 9, 2026 |
Insiders here have filed 2 Form 4s in the last 90 days, but all of them are share awards, grants or other non-market transactions. Those are compensation, not a decision to buy, so they are not scored.
About VYGR
Voyager Therapeutics, Inc. operates as a gene therapy company, concentrating its efforts on developing innovative treatments and pioneering advanced platform technologies. Its leading clinical asset, VY-AADC, is presently undergoing an open-label Phase 1 clinical trial for the management of Parkinson's disease. The company's preclinical portfolio is extensive, featuring VY-SOD102 for amyotrophic lateral sclerosis (ALS), VY-HTT01 for Huntington's disease, and VY-FXN01 for Friedreich's ataxia. Additionally, Voyager is pursuing a Tau program aimed at various tauopathies, including Alzheimer's disease, progressive supranuclear palsy, and frontotemporal dementia, alongside initiatives for spinal muscular atrophy. To advance its gene therapy product pipeline, the company has forged strategic collaboration and licensing agreements with key industry players such as Neurocrine Biosciences, Inc., Pfizer Inc., and Novartis Pharma, A.G. These partnerships cover the research, development, and commercialization of adeno-associated virus-based gene therapy products. Voyager Therapeutics, Inc. was founded in 2013 and maintains its corporate headquarters in Cambridge, Massachusetts.
Analyst consensus
1 firm rating VYGR in the last 3 months, one vote each. Issuer-paid research is not counted.
Next catalysts
- Nov 9, 2026Earnings report
Ask Barron about VYGR
$VYGR stock is featured in our Insider Trades datasets.
→ All Stock ListsRecently reported changes in VYGR holdings by institutional investors
Latest 0 13F filings · Source: SEC EDGAR
View all institutional owners →Insider Trading
Quarterly net insider trading by VYGR's directors and management
Source: SEC EDGAR (Form 4)
Corporate Lobbying
VYGR Estimated quarterly lobbying spending
Source: U.S. Senate LDA
U.S. Patents
New VYGR patent grants
Source: USPTO Open Data Portal
Government Contracts
Estimated quarterly amount awarded to VYGR from public contracts
Source: USAspending.gov
Top ETF Holders
ETFs with the largest estimated holdings in VYGR
| ETF | Est. Holding Size |
|---|---|
| VTIVanguard Morningstar Total Stock Market ETF | $4.48M |
| IWMiShares Russell 2000 ETF | $2.31M |
| VXFVanguard Extended Market ETF | $1.64M |
| IWNiShares Russell 2000 Value ETF | $842.15K |
| VTWOVanguard Russell 2000 ETF | $815.50K |
| IBBiShares Biotechnology ETF | $661.24K |
Estimated from each fund’s disclosed top holdings × AUM
VYGR Insider Score
Our composite score: insider buying, sector, volume, tone & dilution
Bull Case vs Bear Case
AI-generated from VYGR’s recent data — informational, not investment advice